Clinical Trials | Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer – PROSPECT LUNG

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with resectable non-small cell lung cancer (NSCLC) that have had no prior systemic treatment for NSCLC within 5 years except stage 1 and 2 cancers treated with curative intent. The purpose of this study is to compare two usual treatment approaches using approved drugs before and after surgery or only after the surgery to find out which sequence of treatment is better. The study doctors will decide which approach is better by determining which study group was less likely to have their lung cancer grow or spread. In this study, you will either get surgery first, then standard chemotherapy and immune therapy, or you will get standard chemotherapy and immune therapy followed by surgery and then immune therapy. You will get treatment for up to one year after the surgery, until the side effects become too severe, or you want to stop your participation. After you finish your treatment, your doctor will continue to follow your condition every 6 months for up to 3 years, then annually for up to 10 years. Follow-up visits may be in clinic, virtual, or over the phone. If you choose to take part in this study, there is a risk that one of the study approaches may not be as good as the other approach, although both study approaches are approved treatments by the Food and Drug Administration (FDA). There may be some risks that the study doctors do not yet know about. There is evidence that the treatment (chemotherapy and immunotherapy) either before, after, or before and after surgery improves the chance of cure when compared to chemotherapy alone before or after surgery. All of these approaches are already approved and available for your doctor to use. It is not possible to know now if one study approach will extend your life compared to the other study approach. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. Additional information found here: https://clinicaltrials.gov/study/NCT06632327?term=NCT06632327&rank=1 For questions, contact: [email protected]